Results 271 to 280 of about 2,285,924 (374)

1 Molecular and cytogenetic abnormalities in acute myeloid leukaemia and myelodysplastic syndromes [PDF]

, 1996
Georgine E. de Greef, Anne Hagemeijer
openalex   +1 more source

PARP Inhibitors in the Treatment of Prostate Cancer: An Analysis of the Clinical Trial Landscape

Cancer Medicine, Volume 14, Issue 21, November 2025.
ABSTRACT Background Prostate cancer remains one of the most prevalent cancers among men worldwide, particularly in the context of metastatic castration‐resistant prostate cancer (mCRPC), which poses significant treatment challenges. PARP inhibitors offer a promising therapeutic option for patients with homologous recombination repair (HRR) deficiencies.
Yanru Chen, Junjie Cao, Rong Huang, Junyi Lou, Junxian Gu, Zining Luo, Tianliang Yao, Jiebin Xie   +7 more
wiley   +1 more source

Diagnosis of myelodysplastic syndromes: the classic and the novel. [PDF]

Haematologica
Oster HS, Van de Loosdrecht AA, Mittelman M.   +2 more
europepmc   +1 more source

Anaesthetic management of Caesarean section in a patient with Myelodysplastic Syndrome [PDF]

, 1998
K. Hara, Yoji Saito, Noriko Morimoto, Shinichi Sakura, Yoshihiro Kosaka   +4 more
openalex   +1 more source

Clinical effect of point mutations in myelodysplastic syndromes.

New England Journal of Medicine, 2011
R. Bejar, K. Stevenson, O. Abdel-Wahab, N. Galili, B. Nilsson, G. Garcia-Manero, H. Kantarjian, A. Raza, R. Levine, D. Neuberg, B. Ebert   +10 more
semanticscholar   +1 more source

A tour of leukemia progress in 2025, viewed through the MD Anderson leukemia research lens

Cancer, Volume 131, Issue 21, 1 November 2025.
ABSTRACT Advances in the prognostication, monitoring, and treatment of both the acute and chronic leukemias have led to drastically improved outcomes over the past 2 decades. With the advent of targeted therapies, including antibodies such as blinatumomab and inotuzumab and small molecule inhibitors, such as the BCR::ABL1 tyrosine kinase inhibitors ...
Hagop M. Kantarjian, Gautam Borthakur, Naval Daver, Courtney DiNardo, Guillermo Garcia‐Manero, Ghayas Issa, Elias Jabbour, Nitin Jain, Tapan Kadia, Sanam Loghavi, Farhad Ravandi, Guilin Tang, Mary Alma Welch, William Wierda   +13 more
wiley   +1 more source

Research progress on ferroptosis in Myelodysplastic syndromes. [PDF]

Front Pharmacol
Yang Y, Han J, Wei Y, Jin J, Feng W.
europepmc   +1 more source

A nationwide non-interventional epidemiological data registry on myelodysplastic syndromes in Lebanon [PDF]

, 2015
et al.,, Otrock, Zaher K
core   +1 more source

A patient with newly diagnosed breast cancer found to have mosaic TP53 likely pathogenic variant

CA: A Cancer Journal for Clinicians, EarlyView.
Hetal D. Mistry, MacKenzie R. Adams, Charu Taneja, Lauren J. Massingham, Elizabeth H. Dibble, Kara L. Leonard, Jesse Hart, Galina G. Lagos, Mary Anne Fenton   +8 more
wiley   +1 more source

Increased Plasma ST2 Levels Precede the Development of Severe Acute GvHD and Chronic GvHD After Pediatric Hematopoietic Stem Cell Transplantation

Pediatric Blood &Cancer, Volume 72, Issue 11, November 2025.
ABSTRACT Background The suppressor of tumorigenesis 2 (ST2) has emerged as one of the most promising biomarkers for predicting mortality of acute graft‐versus‐host disease (aGvHD) when measured at the onset of symptoms, but detailed time course studies are needed to understand the potential of ST2 as a risk marker of both aGvHD and chronic graft‐versus‐
Nakisa Kamari‐Kany, Sarah Weischendorff, Marianne Ifversen, Denise Elbæk Horan, Christian Enevold, Katrine Kielsen, Klaus Müller   +6 more
wiley   +1 more source